Adding #pembrolizumab to chemotherapy resulted in significantly longer overall survival among patients with previously untreated advanced #triple_negative_breast_cancer whose tumors expressed PD-L1 with a CPS of 10 or more. In the interim analysis of the phase 3 KEYNOTE 355 trial, the addition of pembrolizumab to chemotherapy resulted in longer progression-free survival. Recently, overall survival benefit was confirmed in a report published 2 months ago in New England journal of Medicine by Cortes et al showed that in the CPS-10 subgroup, the median overall survival was 23.0 months in the pembrolizumab–chemotherapy group and 16.1 months in the placebo–chemotherapy group (HR,0.73 P=0.0185).